Marché mondial des infections à streptocoques – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché des infections à streptocoques

Le marché mondial des infections à streptocoques devrait connaître une croissance significative au cours de la période de prévision. Environ 1 femme enceinte sur 4 est porteuse ou colonisée par le streptocoque du groupe B. Selon l'OMS, l'infection à streptocoque du groupe B provoque environ 150 000 mortinaissances et décès de nourrissons évitables chaque année. Environ 21,7 millions de femmes enceintes sont porteuses de cette bactérie, selon la première étude mondiale sur le streptocoque du groupe B.

 Data Bridge Market Research analyse le taux de croissance du marché mondial des infections à streptocoques au cours de la période de prévision 2022-2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché élaboré par l'équipe Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des infections à streptocoques

Market Definition

Streptococcus infections are the kind of bacterial infections that are caused by various strains of Streptococci bacteria. Numerous strains of streptococci can cause different types of infectious diseases such as strep throat, tonsillitis, blood infections, scarlet fever, pneumonia and others

Global Streptococcus Infection Market Dynamics

Drivers

• Rising Adoption of Antibiotics

Clostridium difficile infection is primarily associated with long-term antibiotic use. Increased antibiotic consumption changes the colon bacteria, allowing clostridium difficile bacteria to grow. Antibiotics such as penicillin or amoxicillin are more likely to cause streptococcus infection. The higher use of these antibiotics is increasing the prevalence of clostridium difficile infection, which is most likely to boost the demand for its treatments. Therefore, the more and more consumption of antibiotics acts as a major driver of growth in the global streptococcus infection market.

• Prevalence of streptococcus diseases

The rising incidence of this infection is boosting the growth of the market. For instance, a study by the London School of Hygiene and Tropical Medicine projected that out of 410,000 group B streptococcus cases each year, at least 147,000 stillbirths and infant deaths are projected to occur worldwide. Africa had the highest burden, with 54% of estimated cases and 65% of stillbirths and infant deaths. An increase in the prevalence of group B streptococcus infections and the rate of new infections is possible to drive the global streptococcus infection market.

Opportunities

• Rising Drug Development Activities

Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth in the market by providing doctors with an alternate treatment option. Additionally, the development of a new class of non-antibiotic drugs and vaccines is most likely to open up a large number of opportunities for major market players while also increasing the competition for manufacturing better treatment options. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth in the near future. For instance, in 2017, Pfizer started phase I/II trial of its group B streptococcus conjugate vaccine named PF-06760805, which incorporates at least five serotypes of group B streptococcus and could prevent around 95% of group B streptococcus disease in infants through maternal immunization.

• Increasing Demand for Retail Pharmacies

The rise in the number of these infectious therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could limit the growth of the global streptococcus infection market during a forecast period.

• High Cost For Drug Development

The current treatment options for streptococcus infection are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. Developing a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.  

This global streptococcus infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global streptococcus infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Streptococcus Infection Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. Although, with the relaxation of government restrictions associated with the pandemic and the occurrence of virtual clinical trials, R&D activities started their recovery since 2021.

Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting toward normal patients again. Thus, this will significantly impact the global streptococcus infection market.

Global Streptococcus Infection Market Scope

The global streptococcus infection market is segmented on the basis of bacterial type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Bacterial Type

• Group A
• Group B
• Group C
• Group D
• Group G

Diagnosis

• Antibody Test
• Physical Examination
• Throat culture
• Others

Treatment

• Antibiotics
• Surgery
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Streptococcus Infection Market Regional Analysis/Insights

The global streptococcus infection market is analyzed and market size insights and trends are provided by bacterial type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global streptococcus infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global streptococcus infection market throughout the forecasted period due to latest technology development and the presence of variety of innovative drug molecule to enhance the treatment procedure.  

Asia-Pacific dominates the market due to increased prevalence of bacterial infections and increasing investment in healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Streptococcus Infection Market Share Analysis

Le paysage concurrentiel du marché mondial des infections à streptocoques fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial des infections à streptocoques.

Les principaux acteurs opérant sur le marché mondial des infections à streptocoques comprennent :

• AstraZeneca (Royaume-Uni)
• Lilly (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Novartis SA (Suisse)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Merck & Co., Inc. (États-Unis)
• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Cipla Inc. (Inde)
• Lupin (Inde)

SKU-54660